UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Guidelines for the welfare and use of animals in cancer research

British journal of cancer, 2010-05, Vol.102 (11), p.1555-1577

2010

Volltextzugriff (PDF)

ZD6474 - a novel inhibitor of VEGFR and EGFR tyrosine kinase activity

British journal of cancer, 2005-06, Vol.92 (S1), p.S6-S13

2005

Volltextzugriff (PDF)

ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model

British journal of cancer, 2002-04, Vol.86 (7), p.1157-1161

2002

Volltextzugriff (PDF)

A minimum core outcome dataset for the reporting of preclinical chemotherapeutic drug studies: Lessons learned from multiple discordant methodologies in the setting of colorectal cancer

Critical reviews in oncology/hematology, 2017-04, Vol.112, p.80-102

2017

Volltextzugriff (PDF)

Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours

British journal of cancer, 2003-11, Vol.89 (10), p.1889-1895

2003

Volltextzugriff (PDF)

Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials

Cancer treatment reviews, 1997, Vol.23 (1), p.35-61

1997

Volltextzugriff (PDF)

Reduced capillary perfusion and permeability in human tumour xenografts treated with the VEGF signalling inhibitor ZD4190: an in vivo assessment using dynamic MR imaging and macromolecular contrast media

Magnetic resonance imaging, 2003-10, Vol.21 (8), p.845-851

2003

Volltextzugriff (PDF)

ZD4190 : An orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy

Cancer research (Chicago, Ill.), 2000-02, Vol.60 (4), p.970-975

2000

Volltextzugriff (PDF)

Inhibition of vascular endothelial growth factor signalling using cediranib (RECENTIN; AZD2171) enhances radiation response and causes substantial physiological changes in lung tumour xenografts

British journal of radiology, 2008-10, Vol.81 Spec No 1 (special_issue_1), p.S21-S27

2008

Volltextzugriff (PDF)

The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma

Angiogenesis (London), 2004-12, Vol.7 (4), p.347-354

2004

Volltextzugriff (PDF)

Design and Structure−Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors

Journal of medicinal chemistry, 1999-12, Vol.42 (26), p.5369-5389

1999

Volltextzugriff (PDF)

Phase I trial of temozolomide using an extended continuous oral schedule

Cancer research (Chicago, Ill.), 1998-10, Vol.58 (19), p.4363-4367

1998

Volltextzugriff (PDF)

N-(2-hydroxypropyl)methacrylamide copolymers targeted to the hepatocyte galactose-receptor : pharmacokinetics in DBA2 mice

British journal of cancer, 1991-06, Vol.63 (6), p.859-866

1991

Volltextzugriff (PDF)

Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol)

NMR in biomedicine, 2008-01, Vol.21 (1), p.42-52

2008

Volltextzugriff (PDF)

Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10- dideaza-5,6,7,8-tetrahydrofolic acid (Lometrexol) administered with an oral folic acid supplement

Clinical cancer research, 1995-12, Vol.1 (12), p.1479-1486

1995

Volltextzugriff (PDF)

ZM323881, a Novel Inhibitor of Vascular Endothelial Growth Factor-Receptor-2 Tyrosine Kinase Activity

Microcirculation (New York, N.Y. 1994), 2002-12, Vol.9 (6), p.513-522

2002

Volltextzugriff (PDF)

O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU

British journal of cancer, 1996-05, Vol.73 (9), p.1049-1052

1996

Volltextzugriff (PDF)

3-Aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity

British journal of cancer, 1996-10, Vol.74 (7), p.1030-1036

1996

Volltextzugriff (PDF)

O6-Methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma

British journal of cancer, 1998-11, Vol.78 (9), p.1199-1202

1998

Volltextzugriff (PDF)

Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro

British journal of cancer, 1996-02, Vol.73 (4), p.482-490

1996

Volltextzugriff (PDF)

Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer

Carcinogenesis (New York), 2006-10, Vol.27 (10), p.2133-2139

2006

Volltextzugriff (PDF)

Comparison of the liver subcellular distribution of free daunomycin and that bound to galactosamine targeted N-(2-hydroxypropyl)methacrylamide copolymers, following intravenous administration in the rat

British journal of cancer, 1991-04, Vol.63 (4), p.546-549

1991

Volltextzugriff (PDF)

In vitro evaluation of temozolomide combined with X-irradiation

Anti-cancer drugs, 1997-01, Vol.8 (1), p.92-97

1997

Volltextzugriff (PDF)

Potentiation of temozolomide and BCNU cytotoxicity by O6-benzylguanine : a comparative study in vitro

British journal of cancer, 1996-02, Vol.73 (4), p.482-490

1996

Volltextzugriff (PDF)

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration

Cancer research (Chicago, Ill.), 2002-08, Vol.62 (16), p.4645-4655

2002

Volltextzugriff (PDF)

1 – 25 von 410

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(383)
Mit Volltextzugriff
(329)

Publikationsform

Sprache

Englisch
(410)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Guidelines for the welfare and use of animals in cancer research

ZD6474 - a novel inhibitor of VEGFR and EGFR tyrosine kinase activity

ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model

A minimum core outcome dataset for the reporting of preclinical chemotherapeutic drug studies: Lessons learned from multiple discordant methodologies in the setting of colorectal cancer

Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours

Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials

Reduced capillary perfusion and permeability in human tumour xenografts treated with the VEGF signalling inhibitor ZD4190: an in vivo assessment using dynamic MR imaging and macromolecular contrast media

ZD4190 : An orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy

Inhibition of vascular endothelial growth factor signalling using cediranib (RECENTIN; AZD2171) enhances radiation response and causes substantial physiological changes in lung tumour xenografts

The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma

Design and Structure−Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors

Phase I trial of temozolomide using an extended continuous oral schedule

N-(2-hydroxypropyl)methacrylamide copolymers targeted to the hepatocyte galactose-receptor : pharmacokinetics in DBA2 mice

Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol)

Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10- dideaza-5,6,7,8-tetrahydrofolic acid (Lometrexol) administered with an oral folic acid supplement

ZM323881, a Novel Inhibitor of Vascular Endothelial Growth Factor-Receptor-2 Tyrosine Kinase Activity

O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU

3-Aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity

O6-Methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma

Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro

Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer

Comparison of the liver subcellular distribution of free daunomycin and that bound to galactosamine targeted N-(2-hydroxypropyl)methacrylamide copolymers, following intravenous administration in the rat

In vitro evaluation of temozolomide combined with X-irradiation

Potentiation of temozolomide and BCNU cytotoxicity by O6-benzylguanine : a comparative study in vitro

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration

Suchergebnisse filtern